Contribution through collaboration to develop Corona Virus Vaccine

Phenomenal development of science mandates collaborative research for clubbing myriad domain expertise from all across the corner including academia and industry to come up with a solution to a crisis hitherto unprecedented, as globally experienced presently through novel coronavirus aka Covid19 outbreak.

In India, efforts for finding a solution to this crisis by either developing a preventive vaccine or through a curative medication is underway both from public and private Institutes and Universities as well as from pharmaceutical companies. Amity University has taken an active initiative to forge a global network. Notable progress is expected through Zydus Cadilla’s efforts towards developing a DNA plasmid vaccine.

The global pharmaceutical companies are also expanding their research collaboration with each to fund and fight the novel virus vaccine candidate. Instances of such collaborations include research and development initiatives by 43 global pharma firms among India's Zydus Cadila and Serum Institute, coalition between Glaxosmithkline (GSK) and The University of Queensland (Australia); Glaxosmithkline (GSK) and Epidemic Preparedness Innovations (CEPI); Glaxosmithkline (GSK) and Chinese biotech company clover biopharmaceuticals; Glaxosmithkline (GSK) five partner companies and research groups across the world to develop a novel coronavirus vaccine, US-based Moderna/ NIAID  starting Phase I trials for the vaccine, Commonwealth Serum Laboratories (CSL) and German influenza vaccine specialist Seqirus, with the support of CEPI, are working with the University of Queensland in Australia on an established 'MF59' adjuvant technology, Johnson & Johnson expanded its collaboration with the Biomedical Advanced Research and Development Authority (BARDA) and Beth Israel Deaconess Medical Center (BIDMC), Pfizer and BioNTech have entered into a partnership to co-develop BioNTech's mRNA-based vaccine candidate BNT162, French vaccine major Sanofi has collaborated with  BARDA and CEPI to expedite solutions, Sanofi and US company Translate Bio have announced plans to collaborate on developing a vaccine to beat the coronavirus, Inovio Pharmaceuticals & Beijing Advaccine Biotechnology supported by CEPI to develop a DNA plasmid INO-4800 vaccine, Janssen Pharmaceutical Companies & Beth Israel Deaconess Medical Center funded by BARDA to develop the vaccine, India's Serum Institute of India, in partnership with US-based vaccine specialist Codagenix, is developing a vaccine with de-optimized live attenuated virus.

L. S. Davar and Company, a century old Intellectual Property Law Firm of India, assisting innovators and creators from across over the world, in protecting and enforcing Intellectual properties laud such commendable efforts to save the human race; along with reiterating the commitment to assist the scientific and creative community globally in protecting both the preventive and curative solutions against the present pandemic.